Shares of the clinical-stage biotech Dynavax Technologies Corporation (NASDAQ: DVAX) gained more than 28% in pre-market trading today — soaring more than 40% at the open — after the company announced that the FDA has accepted its response to the Complete Response Letter (CRL) that was previously issued for its experimental hepatitis B vaccine called Heplisav-B.